Inhibrx, Inc.

NasdaqGM:INBX Stock Report

Market Cap: US$1.8b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Inhibrx Management

Management criteria checks 3/4

Inhibrx's CEO is Mark Lappe, appointed in Jan 2010, has a tenure of 14.33 years. total yearly compensation is $2.80M, comprised of 24.1% salary and 75.9% bonuses, including company stock and options. directly owns 5.81% of the company’s shares, worth $103.89M. The average tenure of the management team and the board of directors is 3.3 years and 3.3 years respectively.

Key information

Mark Lappe

Chief executive officer

US$2.8m

Total compensation

CEO salary percentage24.09%
CEO tenure14.3yrs
CEO ownership5.8%
Management average tenure3.3yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

Seeking Alpha • Apr 22

Inhibrx: Spinoff Rumors Send Shares Soaring - Stunning Bull Run Can Continue

Summary Inhibrx Biosciences, Inc. has surged nearly 40% amid rumors of Big Pharma interest in joint spinoffs of INBRX-106 and possibly a second asset. Ozekibart’s Phase 2 data in chondrosarcoma showed a 52% risk reduction in progression or death, positioning INBX as a first-mover in an unmet oncology market. INBRX-106, in combination with Keytruda, is advancing through Phase 2/3 trials, with key data readouts and potential spinoff partnerships as near-term catalysts. Despite strong upside potential and a $300 price target from Stifel, INBX financing remains a risk, with upcoming BLA submissions and pivotal data as critical inflection points. Read the full article on Seeking Alpha
Seeking Alpha • Nov 05

Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform

Summary INBX's two main pipeline candidates, INBRX-109 and INBRX-106, are entering critical late-stage trials with data readouts expected in mid- to late-2025. INBRX-109 targets DR5 in solid tumors, showing promising early results but faces market skepticism due to past failures of similar molecules. Financially, INBX is well-funded with over $200 million in cash and last reported income of $2 billion, providing a potential cash runway through 2025. Given the promising pipeline and strong financial position, I am tentatively optimistic about INBX and recommend a "Buy" rating. Read the full article on Seeking Alpha
Seeking Alpha • Jun 07

Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi

Summary Inhibrx Biosciences, Inc.'s INBRX-109 is a tetravalent drug being developed for the treatment of patients with Ewing Sarcoma and other solid tumor types. It is expected that the Ewing Sarcoma Therapeutics market size could be worth as much as $424.42 million by 2032. INBRX-106 is a hexavalent drug being developed for the treatment of patients with multiple solid tumor types. The global solid tumor therapeutics market is expected to reach $885.44 billion by 2033. Read the full article on Seeking Alpha
Analysis Article • May 13

Is Inhibrx (NASDAQ:INBX) Using Debt Sensibly?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Oct 03

Inhibrx down 8% after announcing webcast for pathway for rare disease candidate

Inhibrx (NASDAQ:INBX) shares fell 8% in after-hours trading Monday after announcing it will hold a webcast on Tuesday morning to discuss the regulatory pathway for INBRX-101 for alpha-1 antitrypsin deficiency (AATD). AATD is an orphan disease affecting ~100K people in the US. It is characterized by low levels of the alpha-1 antitrypsin ("AAT") protein, which causes loss of lung tissue and function, and decreased life expectancy. INBRX-101 is a recombinant human AAT-Fc fusion protein designed to maintain levels of AAT with less frequent dosing compared to currently available therapies. Seeking Alpha's Quant Rating views Inhibrx (INBX) as a hold with high marks for momentum and growth.
Seeking Alpha • Jun 10

Inhibrx: Potential To Move To Registration Study With INBRX-101

Positive results have been released thus far from a phase 1 study using INBRX-101 for the treatment of patients with Alpha-1 Antitrypsin Deficiency. It is expected that the Alpha-1 Antitrypsin Deficiency Augmentation therapy market could reach $1.95 billion by 2026. If FDA gives green light to Inhibrx, then it should be able to initiate a pivotal registration study using INBRX-101 for patients with Alpha-1 Antitrypsin Deficiency 2nd half of 2022. INBRX-109, INBRX-106, INBRX-105, and INBRX-121 are 4 additional drugs in the pipeline being advanced as treatments for cancer; All 4 of these drugs plus INBRX-101 utilize the company's Single-domain antibody technology platform.
Analysis Article • Mar 23

Inhibrx, Inc. (NASDAQ:INBX) Shares Could Be 38% Below Their Intrinsic Value Estimate

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Inhibrx, Inc...

CEO Compensation Analysis

How has Mark Lappe's remuneration changed compared to Inhibrx's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

-US$271m

Dec 31 2023US$3mUS$675k

-US$241m

Sep 30 2023n/an/a

-US$189m

Jun 30 2023n/an/a

-US$172m

Mar 31 2023n/an/a

-US$163m

Dec 31 2022US$1mUS$650k

-US$145m

Sep 30 2022n/an/a

-US$125m

Jun 30 2022n/an/a

-US$111m

Mar 31 2022n/an/a

-US$94m

Dec 31 2021US$5mUS$650k

-US$82m

Sep 30 2021n/an/a

-US$78m

Jun 30 2021n/an/a

-US$78m

Mar 31 2021n/an/a

-US$75m

Dec 31 2020US$869kUS$530k

-US$76m

Sep 30 2020n/an/a

-US$75m

Jun 30 2020n/an/a

-US$74m

Mar 31 2020n/an/a

-US$68m

Dec 31 2019US$864kUS$450k

-US$51m

Compensation vs Market: Mark's total compensation ($USD2.80M) is below average for companies of similar size in the US market ($USD5.66M).

Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.

CEO

Mark Lappe (56 yo)

14.3yrs
Tenure
US$2,802,021
Compensation

Mr. Mark Paul Lappe is Co-founded Inhibrx LLC in 2010. Mr. Lappe co-founded Efficacy Capital Limited in 2004 serves as its President and Managing Partner. Mr. Lappe co-founded Inhibrx in 2010 and serves as...

Leadership Team

NamePositionTenureCompensationOwnership
Mark Lappe
Founder14.3yrsUS$2.80m5.81%
$ 103.9m
Brendan Eckelman
Founder & Chief Scientific Officer14.1yrsUS$1.45m4.5%
$ 80.3m
Kelly Deck
Executive VP & CFO4.1yrsUS$1.15m0%
$ 0
Quinn Deveraux
Founderno datano datano data
Ashraf Amanullah
Executive VP & Chief Technical Operations Officerno datano datano data
Leah Pollema
VP, Corporate Secretary & General Counselno datano datano data
Charbel Helaihel
Vice President of Marketing & Commercial Planning1.3yrsno datano data
Jeffrey Jensen
Executive VP & Chief Clinical Operations Officer4.3yrsno datano data
David Matly
Executive VP and Chief Commercial & Business Development Officer2.6yrsno datano data
Carlos Bais
Executive Vice President of Translational Sciences2yrsno datano data
Josep Garcia
EVP & Chief Clinical Development Officer1.1yrsno datano data
3.3yrs
Average Tenure
49.5yo
Average Age

Experienced Management: INBX's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Mark Lappe
Founder14.3yrsUS$2.80m5.81%
$ 103.9m
Stephen Howell
Member of Advisory Boardno datano datano data
Rand Mulford
Member of Advisory Boardno datano datano data
Douglas Forsyth
Independent Director6.1yrsUS$317.03k1.14%
$ 20.4m
Kimberly Manhard
Independent Director3.9yrsUS$298.03k0%
$ 0
John Kayyem
Independent Director6.1yrsUS$306.53k6.25%
$ 111.7m
Victor Nizet
Member of Advisory Boardno datano datano data
Guy Salvesen
Scientific Advisorno datano datano data
Kristiina Vuori
Independent Director2.6yrsUS$300.53k0%
$ 0
Igor Barjaktarevic
Member of INBRX-101 Scientific Advisory Board2.1yrsno datano data
Mark Brantly
Member of INBRX-101 Scientific Advisory Board2.1yrsno datano data
Kenneth Chapman
Member of INBRX-101 Scientific Advisory Board2.1yrsno datano data
3.3yrs
Average Tenure
59yo
Average Age

Experienced Board: INBX's board of directors are considered experienced (3.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/05/31 00:46
End of Day Share Price 2024/05/29 00:00
Earnings2024/03/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Inhibrx, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Reni BenjaminCitizens JMP Securities, LLC
Joshua SchimmerEvercore ISI